All articles by Heidi Vella

Heidi Vella

Crystal clear: could unlocking proteins provide new cures for anxiety?

New research has revealed for the first time the structure of a protein associated with several anxiety disorders, a discovery that could eventually lead to better drugs. Elly Earls meets the researchers behind the breakthrough to find out more.

Draining cancer’s fuel tank

Cancer is notoriously frustrating to treat because of the high rate of recurrence and metastasis. In many cases, this may be due to cancer stem cells, which conventional therapies struggle to eradicate. However, researchers at the Manchester Institute of Cancer Sciences have suggested these cells might be defeated by blocking their mitochondrial metabolism, in other words draining their ‘fuel tank’. Lead author Professor Michael Lisanti talks to Abi Millar about what the discovery might mean for future treatments.

A new ERA for pulmonary arterial hypertension patients in England

The NHS’s approval of Opsumit, a new drug for pulmonary arterial hypertension (PAH), marks a new era for the treatment of this rare and ultimately fatal disease. Elly Earls speaks to Actelion’s Robin Bhattacherjee and consultant physician Dr Luke Howard to find out why.

Boehringer to close manufacturing lab, losing 1,100 jobs

Boehringer Ingelheim GmbH has announced plans to shutdown its Ben Venue Laboratories unit by the end of the month, cutting 1,100 jobs and putting pressure on the supply of drugs for cancer and other diseases.

GSK and Genmab seek alternative approval for leukaemia drug Arzerra

GlaxoSmithKline and Genmab A/S have announced the submission of leukaemia drug Arzerra to the European Medicines Agency (EMA) for a variation in marketing authorisation.

Aerial Biopharma announce positive Phase II results for narcolepsy drug

A new drug to treat excessive daytime sleepiness associated with narcolepsy has shown positive results from a phase 2b clinical trial, US-based Aerial Biopharma has announced this week.

Common blood pressure drug could help fight tumours

A common blood pressure drug marketed by Merck & Co could help fight cancer tumours, a recent study on mice has revealed.

UK’s cancer drug fund extended to 2016

A £200m-a-year cancer drugs fund due to expire next year will be extended until 2016, UK Prime Minister David Cameron has announced.

Boehringer Ingelheim cancer drug shows positive results in Phase III trial

Boehringer Ingelheim’s LUME-Lung 1 Phase III clinical trial of novel investigational compound nintedanib has provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma histology.

UK cancer study group to co-fund research into new cancer treatment

The Cancer Research Technology Pioneer Fund CPF has announced it has chosen a study to develop a promising class of MPS1 inhibitors for the treatment of cancer as its first investment project.